
Curative Health Insurance Company has secured over $150 million in Series B funding, pushing the company to unicorn status with a valuation of $1.275 billion. The investment signals strong market confidence in Curative's unconventional approach to employer-based health coverage.
The numbers back it up. Membership quadrupled in both 2023 and 2024, and the company is on track to nearly double again in 2025. With this projected growth, annual recurring revenue is set to exceed $1 billion.
The round was led by Upside Vision Fund, chaired by TED's Chris Anderson. Justin Mateen, founder of JAM Fund and one of Tinder's co-founders, contributed $47.5 million through personal and fund investments. Other notable participants include Mike Novogratz of Galaxy Digital, Stanley Druckenmiller's Duquesne Family Office, DCVC, and Martin Varsavsky.
Curative has positioned itself as a direct competitor to the dominant BUCA carriers (Blues, United, Cigna, Aetna). The company's model eliminates out-of-pocket costs entirely. Members pay no co-pays, deductibles, or coinsurance as long as they complete an annual preventive health visit called the Baseline Visit.
This approach has produced measurable results. Curative reports a 20% increase in primary care engagement, a 30% reduction in hospitalizations, and drug cost savings of up to 40% within a year of employers joining the plan. The company attributes these outcomes to removing financial barriers that typically discourage people from seeking care early.
"Curative's mission is to eliminate financial barriers and guide our members at every step of their health journey," said Fred Turner, CEO and co-founder. "This funding validates the disruptive model we've built, which leverages AI-driven technology, real human support, and aligned incentives to actually improve outcomes."
The Series B capital will fund Curative's national expansion strategy. The company plans to enter Mid-Atlantic states in the near term, building on its current operations in Texas, Florida, and Georgia. A portion of the funding will strengthen reserves to meet state regulatory requirements and maintain financial strength ratings.
Additional investments will target member health engagement programs, AI-powered operational capabilities, and network development. The company is also pursuing modernized payment methods to streamline how providers get reimbursed.
Traditional insurance networks often limit where members can receive care and lack pricing transparency. Curative is addressing this through what it calls the Curative Cash Card. The card extends $0 care access to over a million providers nationwide, beyond typical network boundaries.
The system pays providers instantly at the point of care. This eliminates the billing delays and administrative complexity that frustrate both patients and healthcare providers under conventional insurance arrangements. Combined with broader national network partnerships, the card aims to create a smoother experience than legacy insurers can offer.
Founded less than three years ago, Curative now serves more than 1,200 employer clients and over 165,000 members. The company has reached profitability, a rare achievement for a health insurance startup at this stage.
The company's trajectory reflects the unconventional path of its CEO and co-founder, Fred Turner. A scientist by training, Turner previously founded multiple venture-backed biotech startups, including Shield Bio and TL Biolabs. Before pivoting to insurance, he led Curative as it became the leading COVID-19 testing provider in the country. Working directly with payers during the pandemic gave him a front-row seat to the inefficiencies plaguing American healthcare, and that experience shaped his conviction that employer-based coverage needed a complete rethink.
Turner has landed on Forbes' "30 Under 30" list and been named an Austin Business Journal Power Player two years running. But his focus remains on something bigger than accolades: building a system where financial barriers don't stand between patients and the care they need.
Curative holds an A- rating from AM Best, the credit rating agency specializing in the insurance industry. The company offers employers a competitive monthly premium with zero additional costs for members who complete their Baseline Visit within 120 days of their plan start date.
Justin Mateen was Curative's first investor. Despite his initial stake compounding more than 400-fold, he increased his position in this round. "Curative is reimagining health insurance from first principles," Mateen said. "The best companies are built by founders who take on problems most people consider unsolvable. Fred is one of those rare founders, and what Curative is building has the potential to reshape healthcare for millions."
Turner sees the timing as ideal. "For years, industry watchers and employers have talked about an inflection point where lack of innovation, rising frustration, and runaway healthcare costs would collide," he said. "Curative is leading that change moment. We are benefiting from the industry's urgent demand for simplicity, predictability, and real improvement—and we are uniquely positioned to deliver it at a national scale."

